Effects of the radiosensitising agent nicotinamide on relative tissue perfusion and kidney function in C3H mice.

[1]  S. Dische,et al.  Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  N. Bleehen,et al.  BW12C: effects on tumour hypoxia, tumour thermosensitivity and relative tumour and normal tissue perfusion in C3H mice. , 1991, British Journal of Cancer.

[3]  J. Collier,et al.  A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  N. Bleehen,et al.  A study of the mechanism of hydralazine enhancement of thermal damage in the KHT tumour. , 1991, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[5]  J. Brown,et al.  Structure-activity relationships for tumour radiosensitization by analogues of nicotinamide and benzamide. , 1991, International journal of radiation biology.

[6]  G. Adams,et al.  The measurement of radiosensitizer-induced changes in mouse tumor metabolism by 31P magnetic resonance spectroscopy. , 1991, International journal of radiation oncology, biology, physics.

[7]  M. Horsman,et al.  Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. , 1991, British Journal of Cancer.

[8]  J. Overgaard,et al.  Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. , 1990, Cancer research.

[9]  J. Overgaard,et al.  The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo. , 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  M. Trotter,et al.  Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. , 1990, Journal of the National Cancer Institute.

[11]  J. Overgaard,et al.  Radiosensitization by nicotinamide in tumors and normal tissues: the importance of tissue oxygenation status. , 1989, International journal of radiation oncology, biology, physics.

[12]  J. Brown,et al.  Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. , 1989, Radiation research.

[13]  J. Overgaard,et al.  Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. , 1989, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[14]  J. Brown,et al.  Mechanism of action of the selective tumor radiosensitizer nicotinamide. , 1988, International journal of radiation oncology, biology, physics.

[15]  R. Pero,et al.  Comparison of low dose nicotinamide versus benzamide, administered per os, as radiosensitizers in a C3H mammary carcinoma. , 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  R. Jirtle,et al.  Chemical modification of tumour blood flow. , 1988, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[17]  A. C. Begg,et al.  Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. , 1988, British Journal of Cancer.

[18]  M. Horsman,et al.  Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. , 1987, Radiation research.

[19]  D. M. Brown,et al.  Preferential tumor radiosensitization by analogs of nicotinamide and benzamide. , 1986, International journal of radiation oncology, biology, physics.

[20]  D. M. Brown,et al.  Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase. , 1986, British Journal of Cancer.

[21]  F. Stewart,et al.  Blood flow changes in transplanted mouse tumours and skin after mild hyperthermia. , 1983, The British journal of radiology.

[22]  M. Williams,et al.  Sequential functional testing of radiation-induced renal damage in the mouse. , 1983, Radiation research.

[23]  J. D. de Vries,et al.  Determination of nicotinamide in human plasma and urine by ion-pair reversed-phase high-performance liquid chromatography. , 1980, Journal of chromatography.

[24]  J. Gray,et al.  A new mouse tumor model system (RIF-1) for comparison of end-point studies. , 1980, Journal of the National Cancer Institute.

[25]  D. Alberts,et al.  Hydrolysis and protein binding of melphalan. , 1978, Journal of pharmaceutical sciences.

[26]  J. Boyer,et al.  Hepatic toxicity from large doses of vitamin B3 (nicotinamide). , 1973, The New England journal of medicine.

[27]  A. Hoffer.  Megavitamin B-3 Therapy for Schizophrenia , 1971, Canadian Psychiatric Association journal.

[28]  G. H. Greenbaum.  An evaluation of niacinamide in the treatment of childhood schizophrenia. , 1970, The American journal of psychiatry.

[29]  L. Sapirstein,et al.  Regional blood flow by fractional distribution of indicators. , 1958, The American journal of physiology.

[30]  N. Bleehen,et al.  Comparative effects of hydralazine on perfusion of KHT tumor, kidney and liver and on renal function in mice. , 1992, International journal of radiation oncology, biology, physics.

[31]  P. Kristjansen,et al.  Biochemical and physiological changes induced by nicotinamide in a C3H mouse mammary carcinoma and CDF1 mice. , 1992, International journal of radiation oncology, biology, physics.

[32]  A. Rojas.  Radiosensitization with normobaric oxygen and carbogen. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  J. Overgaard,et al.  Mechanism for the reduction of tumour hypoxia by nicotinamide and the clinical relevance for radiotherapy. , 1989, Biomedica biochimica acta.

[34]  D. Hawkins.  Treatment of schizophrenia based on the medical model. , 1968 .